1k citations
- Roche (Switzerland)CH5 papers
- Novartis (Switzerland)CH4 papers
- Science Wares (United States)US4 papers
- University of TorontoCA4 papers
- Bayer (Germany)DE3 papers
- Google (United States)US3 papers
- Imperial College LondonGB3 papers
- Pacific Northwest National LaboratoryUS3 papers
- AstraZeneca (United Kingdom)GB2 papers
- Boehringer Ingelheim (China)CN2 papers
- Boehringer Ingelheim (Egypt)EG2 papers
- Bristol-Myers Squibb (Germany)DE2 papers
4 papers · 1 filter
Duration of and time to response in oncology clinical trials from the perspective of the estimand framework
Hans-Jochen Weber, Stephen Corson, Jiang Li +6
Duration of response (DOR) and time to response (TTR) are typically evaluated as secondary endpoints in early-stage clinical studies in oncology when efficacy is assessed by the be…
Learning image representations for anomaly detection: application to discovery of histological alterations in drug development
Igor Zingman, Birgit Stierstorfer, Charlotte Lempp +1
We present a system for anomaly detection in histopathological images. In histology, normal samples are usually abundant, whereas anomalous (pathological) cases are scarce or not a…
The use of external controls: To what extent can it currently be recommended?
Hans Ulrich Burger, Christoph Gerlinger, Chris Harbron +4
With more and better clinical data being captured outside of clinical studies and greater data sharing of clinical studies, external controls may become a more attractive alternati…
Reliably assessing the electronic structure of cytochrome P450 on today's classical computers and tomorrow's quantum computers
Joshua J. Goings, Alec White, Joonho Lee +6
An accurate assessment of how quantum computers can be used for chemical simulation, especially their potential computational advantages, provides important context on how to deplo…